Hypertension, affecting approximately 1.3 billion people globally, can lead to severe health issues like heart attacks and strokes. A new drug, baxdrostat, has emerged as a promising treatment for patients who do not respond to conventional medications. In the BaxHTN Phase III trial, led by Professor Bryan Williams from the UCL Institute of Cardiovascular Science and funded by AstraZeneca, nearly 800 patients were tested across 214 clinics worldwide. The study found that after 12 weeks, patients taking baxdrostat experienced a reduction in systolic blood pressure by 9-10 mmHg compared to the placebo group. Notably, around 40% of those on baxdrostat achieved target blood pressure levels of under 130/80 mmHg, significantly higher than the 20% in the placebo group. Another trial, Bax24, reported even more substantial results, with a 14 mmHg reduction in blood pressure. Baxdrostat functions by blocking aldosterone synthase, a key enzyme responsible for increasing blood pressure by causing the body to retain salt and water. This innovative approach addresses the underlying issues in patients with resistant hypertension, providing hope for more effective treatment options in the future.